TMEM106A Antikörper (N-Term)
Kurzübersicht für TMEM106A Antikörper (N-Term) (ABIN1450139)
Target
Reaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- N-Term
-
Kreuzreaktivität (Details)
- Species reactivity (tested):Human, Mouse
-
Aufreinigung
- Affinity chromatography purified via peptide column
-
Immunogen
- 14 amino acid synthetic peptide near the amino terminus of human TMEM106A
-
Isotyp
- IgG
-
-
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Konzentration
- 1.0 mg/mL
-
Buffer
- PBS containing 0.02 % Sodium Azide as preservative
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Handhabung
- Avoid repeated freezing and thawing.
-
Lagerung
- 4 °C/-20 °C
-
Informationen zur Lagerung
- Store undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
-
-
- TMEM106A (Transmembrane Protein 106A (TMEM106A))
-
Andere Bezeichnung
- TMEM106A
-
Hintergrund
- Transmembrane protein 106A (TMEM106A) is a single-pass transmembrane protein that is closely related to TMEM106B, a protein that is thought to be a novel risk factor for frontotemporal lobar degeneration (FTLD), a group of clinically, pathologically and genetically heterogeneous disorders associated with atrophy in the frontal lobe and temporal lobe of the brain. The actual roles of TMEM106A and TMEM106B are still undetermined, however, as TMEM106B is involved in FTLD, it is possible that TMEM106A may also be a risk factor for FTLD.Synonyms: Transmembrane protein 106A
-
Gen-ID
- 113277
-
NCBI Accession
- NP_659478
Target
-